Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) Return on Equity: 2017-2025

Historic Return on Equity for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to 1.58%.

  • UroGen Pharma's Return on Equity rose 571.00% to 1.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.58%, marking a year-over-year increase of 571.00%. This contributed to the annual value of 3.43% for FY2024, which is 211.00% up from last year.
  • UroGen Pharma's Return on Equity amounted to 1.58% in Q3 2025, which was down 28.84% from 2.22% recorded in Q2 2025.
  • UroGen Pharma's 5-year Return on Equity high stood at 26.16% for Q1 2022, and its period low was -15.18% during Q4 2024.
  • Over the past 3 years, UroGen Pharma's median Return on Equity value was 1.58% (recorded in 2025), while the average stood at 1.78%.
  • As far as peak fluctuations go, UroGen Pharma's Return on Equity skyrocketed by 2,758bps in 2022, and later slumped by 2,507bps in 2023.
  • UroGen Pharma's Return on Equity (Quarterly) stood at -5.55% in 2021, then skyrocketed by 699bps to 1.44% in 2022, then surged by 47bps to 1.91% in 2023, then crashed by 1,709bps to -15.18% in 2024, then surged by 571bps to 1.58% in 2025.
  • Its Return on Equity was 1.58% in Q3 2025, compared to 2.22% in Q2 2025 and 5.01% in Q1 2025.